# COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer

Source: https://onco.cc/key-papers/paper-nct04068610-br-j-cancer-2024/  
OnCo record `paper-nct04068610-br-j-cancer-2024` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Published report from the COLUMBIA-1 trial registered as NCT04068610, in British Journal of Cancer (2024), chosen as the most cited paper whose own text cites the registry id.

## Summary

Background: To determine whether the addition of durvalumab (anti-PD-L1) and oleclumab (anti-CD73) to standard-of-care treatment (FOLFOX and bevacizumab) enhances the anti-tumour effect in patients with metastatic colorectal cancer (mCRC).

Methods: COLUMBIA-1 (NCT04068610) was a Phase Ib (feasibility; Part 1)/Phase II (randomised; Part 2) trial in patients with treatment-naïve microsatellite stable mCRC. Patients in Part 2 were randomised to receive standard-of-care (control arm) or standard-of-care plus durvalumab and oleclumab (experimental arm). Primary objectives included safety and efficacy.

Results: Seven patients were enrolled in Part 1 and 52 in Part 2 (n = 26 in each arm). Grade ≥3 treatment-emergent adverse events (TEAE) occurred in 80.8% and 65.4% of patients in the control and experimental arms of Part 2, respectively, with 26.9% and 46.3% experiencing serious TEAEs. The confirmed objective response rate (ORR) was numerically higher in the experimental arm compared with the control arm (61.5% [95% confidence interval (CI), 40.6-79.8] vs 46.2% [95% CI, 26.6-66.6]) but did not meet the statistically significant threshold in either arm.

Conclusion: The safety profile of FOLFOX and bevacizumab in combination with durvalumab and oleclumab was manageable; however, the efficacy results do not warrant further development of this combination in patients with microsatellite stable mCRC.

Registration: NCT04068610.

Indexed on Europe PMC as PubMed record 39048638 (DOI 10.1038/s41416-024-02796-3). Its abstract cites the registry id NCT04068610, which is how it was matched to this trial; no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: British Journal of Cancer
- Year: 2024
- DOI: 10.1038/s41416-024-02796-3
- Authors: Segal NH, Tie J, Kopetz S, et al.
- What it means: This is the paper Europe PMC returns for registry id NCT04068610 with the most citations, so it is the natural first reading for anyone following the COLUMBIA-1 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
- Caveats: Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.

## Sources

- Br J Cancer 2024: https://doi.org/10.1038/s41416-024-02796-3
- PubMed: https://pubmed.ncbi.nlm.nih.gov/39048638/
- Europe PMC: https://europepmc.org/article/MED/39048638
- ClinicalTrials.gov NCT04068610: https://clinicaltrials.gov/study/NCT04068610

## Connected records

- trials: [COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC](https://onco.cc/trials/nct04068610/)
- journals: [British Journal of Cancer](https://onco.cc/journals/british-journal-of-cancer/)

---
JSON: https://onco.cc/api/v1/entities/paper-nct04068610-br-j-cancer-2024.json